Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BALANCED SALT vs PENTOTHAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Balanced salt solutions are used for irrigation and replacement of extracellular fluid. They provide essential ions (sodium, potassium, calcium, magnesium, chloride, bicarbonate) to maintain osmotic balance and p H homeostasis. The mechanism involves restoration of electrolyte composition and fluid volume without direct pharmacological activity.
Potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission; also reduces excitatory glutamate signaling.
Intraocular irrigation during ophthalmic surgery,Irrigation of wounds, body cavities, and tissues during surgical procedures,Replacement of extracellular fluid in hypovolemia (off-label)
Induction of general anesthesia,Induction of coma for increased intracranial pressure,Status epilepticus (off-label)
Intraocular irrigation during surgery: sufficient volume to maintain anterior chamber depth. Also used as IV fluid: 500-1000 m L bolus, then 50-100 m L/hour continuous infusion for volume replacement.
Induction: 3-5 mg/kg IV; Maintenance: 25-75 mg IV as needed; Rectal: 25 mg/kg (max 1.5 g) for induction.
Not applicable; components (sodium, chloride, potassium, calcium, magnesium, acetate, citrate) are endogenous and rapidly equilibrated; clinical context: no terminal elimination half-life as they are physiologic substances
Terminal elimination half-life is 5-12 hours (mean 8 hours) in adults. Prolonged with hepatic impairment, obesity, or high doses due to saturation of redistribution and metabolism.
Not metabolized; components are directly excreted or incorporated into physiological pools. Excess ions are eliminated via renal excretion.
Hepatic; primarily via CYP2C9 and other CYP450 enzymes.
Renal: >95% of electrolytes and water eliminated unchanged via kidneys (glomerular filtration and tubular reabsorption dynamics); biliary/fecal: <5%
Hepatic metabolism (approx. 80%), renal excretion of metabolites (20-30%) and unchanged drug (0.3-1%). Biliary/fecal elimination is negligible.
Minimal to none; electrolytes are free in solution; no significant binding to plasma proteins (e.g., albumin, globulins)
Approximately 72-86% bound, primarily to albumin (with some binding to lipoproteins).
Approximately 0.2 L/kg (extracellular fluid volume); clinically indicates distribution primarily into interstitial and intravascular spaces
Vd = 1.0-2.5 L/kg (mean 1.5 L/kg). High Vd due to extensive tissue distribution, including brain and fat; correlates with high lipid solubility.
Intravenous: 100%; ophthalmic: Not applicable (topical administration delivers directly to site, systemic absorption negligible)
IV: 100%. Rectal: approximately 60-80% (with variability). IM: approximately 60-70%. Oral: negligible due to extensive first-pass metabolism (not used clinically).
No dose adjustment required for intraocular use. For IV use, caution in severe renal impairment (e GFR <30 m L/min) with monitoring for electrolyte imbalances; consider reducing infusion rate.
No specific GFR-based adjustment; use with caution in severe renal impairment due to prolonged effects.
No adjustment required for either route; balanced salt solution is not hepatically metabolized.
Reduce dose by 50% in Child-Pugh B and C; monitor for prolonged sedation.
Intraocular: as per surgeon's discretion. IV: weight-based, 10-20 m L/kg bolus then 2-5 m L/kg/hour continuous infusion for volume depletion.
Induction: 5-6 mg/kg IV; Maintenance: 1-2 mg/kg IV as needed; Rectal: 25 mg/kg (max 1.5 g).
No specific dose adjustment; monitor for fluid overload and electrolyte disturbances, especially in patients with cardiac or renal compromise.
Reduce induction dose to 2-3 mg/kg IV; use lower maintenance doses; increased risk of hypotension and respiratory depression.
None.
WARNING: RESPIRATORY DEPRESSION AND APNEA; RESUSCITATIVE EQUIPMENT AND PERSONNEL MUST BE IMMEDIATELY AVAILABLE. INTRA-ARTERIAL INJECTION MAY CAUSE ARTERIAL SPASM, THROMBOSIS, AND GANGRENE.
Hypersensitivity reactions may occur,Use with caution in patients with renal impairment due to risk of electrolyte overload,Monitor serum electrolytes and fluid balance during prolonged use,Do not use if solution is discolored or contains particulate matter
Respiratory depression, hypotension, laryngospasm, bronchospasm, cardiac arrhythmias, extravasation risk, and acute porphyria exacerbation.
Hypersensitivity to any component,Severe electrolyte disturbances (e.g., hyperkalemia, hypernatremia),Hepatic failure (relative contraindication due to fluid overload risk)
Hypersensitivity to barbiturates, acute porphyria, severe respiratory or cardiovascular instability, and inadequate airway management capability.
No known food interactions. Maintain normal hydration unless otherwise instructed.
No specific food interactions. However, avoid alcohol for at least 24 hours due to additive CNS depression.
No evidence of teratogenic risk; considered safe during all trimesters when used as directed (topical ophthalmic).
PENTOTHAL (thiopental) crosses the placenta. First trimester: limited human data, animal studies show no consistent teratogenicity. Second trimester: no specific malformation risk. Third trimester: prolonged maternal administration may cause neonatal respiratory depression, hypotonia, and withdrawal. Use only if clearly needed.
No known risk during breastfeeding; M/P ratio not available, but systemic absorption is minimal.
Thiopental is excreted in breast milk. M/P ratio is approximately 0.4–0.8. Infant dose is low (<1% of maternal weight-adjusted dose), but caution is advised due to potential CNS depression. American Academy of Pediatrics considers compatible with breastfeeding, but monitor infant for sedation.
No dose adjustments required during pregnancy due to negligible systemic absorption.
Pregnancy may increase volume of distribution and clearance, but dosing adjustments for thiopental are not routinely recommended. Use lowest effective dose due to increased sensitivity to barbiturates. For cesarean section, standard induction doses (3-5 mg/kg IV) are used; reduced doses may be needed if combined with other sedatives.
Use a sterile technique for intraocular irrigation. Avoid prolonged corneal exposure. Discard unused solution immediately. Monitor intraocular pressure post-procedure.
Pentothal (thiopental) is an ultra-short-acting barbiturate used for induction of anesthesia. It causes dose-dependent respiratory depression and hypotension. Administer only in a controlled setting with resuscitation equipment. Note that it is highly alkaline (p H 10-11) and extravasation causes severe tissue necrosis. Also, it is contraindicated in porphyria.
Report any eye pain, redness, or vision changes immediately.,Do not touch the dropper tip to any surface.,Use as directed by your surgeon.,Discard bottle after single use.
You will receive this medication only under the supervision of an anesthesiologist.,It will cause you to fall asleep quickly and you may feel drowsy for several hours after the procedure.,Do not drive or operate machinery for at least 24 hours after receiving this medication.,Inform your doctor if you have a history of porphyria, liver disease, or allergies to barbiturates.,You may experience a bad taste or cough upon injection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BALANCED SALT vs PENTOTHAL, answered by our medical review team.
BALANCED SALT is a Ophthalmic Solution that works by Balanced salt solutions are used for irrigation and replacement of extracellular fluid. They provide essential ions (sodium, potassium, calcium, magnesium, chloride, bicarbonate) to maintain osmotic balance and p H homeostasis. The mechanism involves restoration of electrolyte composition and fluid volume without direct pharmacological activity.. PENTOTHAL is a Barbiturate Anesthetic that works by Potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission; also reduces excitatory glutamate signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BALANCED SALT and PENTOTHAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BALANCED SALT is: Intraocular irrigation during surgery: sufficient volume to maintain anterior chamber depth. Also used as IV fluid: 500-1000 m L bolus, then 50-100 m L/hour continuous infusion for volume replacement.. The standard adult dose of PENTOTHAL is: Induction: 3-5 mg/kg IV; Maintenance: 25-75 mg IV as needed; Rectal: 25 mg/kg (max 1.5 g) for induction.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BALANCED SALT and PENTOTHAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BALANCED SALT is classified as Category C. No evidence of teratogenic risk; considered safe during all trimesters when used as directed (topical ophthalmic).. PENTOTHAL is classified as Category C. PENTOTHAL (thiopental) crosses the placenta. First trimester: limited human data, animal studies show no consistent teratogenicity. Second trimester: no specific malformation risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.